Sarah Jefferies
YOU?
Author Swipe
View article: Temporal reconstruction of a Salmonella Enteritidis ST11 outbreak in New Zealand
Temporal reconstruction of a Salmonella Enteritidis ST11 outbreak in New Zealand Open
Outbreaks caused by Salmonella Enteritidis are commonly linked to eggs and poultry meat internationally, but this serovar had never been detected in Aotearoa New Zealand (NZ) poultry prior to 2021. Locally designated genomic cluster Salmon…
View article: Transforming molecular neuropathology for adult brain tumour patients in the UK: Insights on implementation, adoption, and patient access (2021-2024)
Transforming molecular neuropathology for adult brain tumour patients in the UK: Insights on implementation, adoption, and patient access (2021-2024) Open
Background Molecular neuropathology is evolving rapidly, driven by novel genomic technologies, national policies, and the urgent need for precision brain tumor care. Inequity in access to genomic testing highlighted in previous reports war…
View article: A decade of genomic surveillance tracks the disappearance and reintroduction of seasonal influenza virus in Aotearoa New Zealand
A decade of genomic surveillance tracks the disappearance and reintroduction of seasonal influenza virus in Aotearoa New Zealand Open
Seasonal influenza virus circulation was eliminated in Aotearoa (New Zealand) from 2020 to 2022, following the nation's stringent public health response to the COVID-19 pandemic. Here, we generate nearly 4,000 influenza virus genomes captu…
View article: Shiga toxin-producing Escherichia coli illness in Aotearoa | New Zealand, 2016-2022: epidemiological, genomic and traditional typing analyses provide insight into a significant endemic disease while highlighting knowledge gaps
Shiga toxin-producing Escherichia coli illness in Aotearoa | New Zealand, 2016-2022: epidemiological, genomic and traditional typing analyses provide insight into a significant endemic disease while highlighting knowledge gaps Open
Introduction Shiga toxin producing Escherichia coli (STEC) cause significant endemic disease in Aotearoa | New Zealand (NZ) with a 2022 case incidence rate of 19.9/100,000 population. The introduction of culture independent diagnostic test…
View article: Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial Open
Cancer Research UK.
View article: Ethnic equity in Aotearoa New Zealand's COVID-19 response: A descriptive epidemiological study
Ethnic equity in Aotearoa New Zealand's COVID-19 response: A descriptive epidemiological study Open
Despite achieving a low overall burden of disease by international comparisons, the multi-faceted New Zealand response did not prevent stark ethnic inequities in access to vaccination and COVID-19 outcomes. Policies which address dispariti…
View article: Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial Open
Background Glioblastoma confers a bleak prognosis, with median survival of less than a year. This trial evaluated whether addition of the CTLA-4 immune checkpoint inhibitor ipilimumab to standard therapy improves survival in patients with …
View article: A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1–10 Brain Metastases
A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1–10 Brain Metastases Open
A phase III randomised trial of HS-WBRT was shown not to be feasible at this time in the UK. As most randomised trials of HS-WBRT reported to date share common endpoints, including NCF, an individual patient data meta-analysis should be un…
View article: Intra-operative extracorporeal irradiation of tumour-invaded craniotomy bone flap in meningioma: a case series
Intra-operative extracorporeal irradiation of tumour-invaded craniotomy bone flap in meningioma: a case series Open
Background Extracorporeal irradiation of tumorous calvaria (EITC) can be performed to restore function and form of the skull after resection of bone-invasive meningioma. We sought to examine the rate of tumour recurrence and other selected…
View article: Adult brain tumour research in 2024: Status, challenges and recommendations
Adult brain tumour research in 2024: Status, challenges and recommendations Open
In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government pledging £20m of f…
View article: Impact of the COVID‐19 related border restrictions on influenza and other common respiratory viral infections in New Zealand
Impact of the COVID‐19 related border restrictions on influenza and other common respiratory viral infections in New Zealand Open
Background New Zealand's (NZ) complete absence of community transmission of influenza and respiratory syncytial virus (RSV) after May 2020, likely due to COVID‐19 elimination measures, provided a rare opportunity to assess the impact of bo…
View article: Treatment outcomes and locoregional recurrence in head and neck cancer
Treatment outcomes and locoregional recurrence in head and neck cancer Open
View article: Data from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Data from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma Open
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-sp…
View article: Data from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Data from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
Purpose:Patients with recurrent high-grade gliomas (HGG) are usually managed with alkylating chemotherapy ± bevacizumab. However, prognosis remains very poor. Preclinically, we showed that HGGs are a target for arginine depletion with pega…
View article: Figure S3 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Figure S3 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
Effects of ADI-PEG20 on the folate pathway
View article: Data from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Data from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
Purpose:Patients with recurrent high-grade gliomas (HGG) are usually managed with alkylating chemotherapy ± bevacizumab. However, prognosis remains very poor. Preclinically, we showed that HGGs are a target for arginine depletion with pega…
View article: Figure S3 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Figure S3 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
Effects of ADI-PEG20 on the folate pathway
View article: Additional Tables and Figures from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Additional Tables and Figures from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma Open
Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-…
View article: Figure S2 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Figure S2 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
Kaplan Meier plots for PFS and OS
View article: Figure S1 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Figure S1 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
ASS1 immunohistochemistry
View article: Additional Tables and Figures from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Additional Tables and Figures from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma Open
Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-…
View article: Figure S1 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Figure S1 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
ASS1 immunohistochemistry
View article: Figure S2 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma
Figure S2 from A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma Open
Kaplan Meier plots for PFS and OS
View article: Data from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
Data from A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma Open
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-sp…
View article: Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression
Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression Open
Background Radiation treatment of benign tumors in tumor predisposition syndromes is controversial, but short-term studies from treatment centers suggest safety despite apparent radiation-associated malignancy being reported. We determined…
View article: Temporal associations of the COVID-19 related border restrictions and respiratory viral infections in New Zealand
Temporal associations of the COVID-19 related border restrictions and respiratory viral infections in New Zealand Open
New Zealand (NZ)’s elimination of community transmission of influenza and respiratory syncytial virus (RSV) infections in May 2020, due to stringent COVID-19 countermeasures, provided a rare opportunity to assess the impact of border restr…
View article: Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-<sup>13</sup>C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study
Imaging Glioblastoma Metabolism by Using Hyperpolarized [1-<sup>13</sup>C]Pyruvate Demonstrates Heterogeneity in Lactate Labeling: A Proof of Principle Study Open
Purpose To evaluate glioblastoma (GBM) metabolism by using hyperpolarized carbon 13 (13C) MRI to monitor the exchange of the hyperpolarized 13C label between injected [1-13C]pyruvate and tumor lactate and b…
View article: Does Experiencing Discrimination in the Workplace Change Opinion? A Mediation Analysis of Identity and Support for Affirmative Action
Does Experiencing Discrimination in the Workplace Change Opinion? A Mediation Analysis of Identity and Support for Affirmative Action Open
Affirmative action policies have been a popular topic in U.S. media since their inception in the Civil Rights Act 1964. Previous studies note that race, gender, and political identity are known influencers of support for affirmative action…
View article: Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma Open
In our review, most techniques (except G-banding) appeared to have good sensitivity (few false negatives) for detection of 1p/19q codeletions in glioma against both FISH and PCR-based LOH as a reference standard. However, we judged the cer…
View article: Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta‐analysis based on a Cochrane systematic review Open
Codeletion of chromosomal arms 1p and 19q, in conjunction with a mutation in the isocitrate dehydrogenase 1 or 2 gene, is the molecular diagnostic criterion for oligodendroglioma, IDH mutant and 1p/19q codeleted. 1p/19q codeletion is a dia…